AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — FY2016 Earnings Presentation

33 slides from AMAG Pharmaceuticals's earnings presentation, Feb 14, 2017

  1. Slide 1: AMAG Pharmaceuticals 2016 Financial Results and Intrarosa License Agreement

    AMAG Pharmaceuticals 2016 Financial Results and Intrarosa License Agreement February 14, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, st

  3. Slide 3: Today's Agenda

    Today’s Agenda 3 2016 Highlights and Recent Events1 5 Value Drivers and Upcoming Potential Product Launches 4 IntrarosaTM: Further Expansion into Women’s Health 3 2016 Financial Overview 6 Q&A 2 2016 Product Performance and 2017 Growth Drivers

  4. Slide 4: 2016 Highlights and Recent Events

    2016 Highlights and Recent Events

  5. Slide 5: 2016 Highlights and Recent Events

    2016 Highlights and Recent Events  Makena  Drove 44% quarterly sales growth over 4Q-2015 and 33% growth year over year through: ‒ Successful launch of single-dose, preservative free formulation ‒ Expansion of Makena @Home service, including enhanced agreement with Optum Home Health  Completed Mak

  6. Slide 6: Further Expanding AMAG's Product Portfolio

    Further Expanding AMAG’s Product Portfolio 6 Pregnancy & Birth Wellness Post-Menopausal Health Feraheme Makena Velo Option Cord Blood Registry Used for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) The only FDA-approved therapy to reduce recurrent

  7. Slide 7: Makena: Strong Commercial Execution

    7 $67.4 $97.2 4Q-2015 4Q-2016 Makena: Strong Commercial Execution $251.6 $334.1 2015 2016 Fourth Quarter Revenue ($M) Full Year Revenue ($M) W O M E N ’ S H E A L T H : M A K E N A 2017 Growth Drivers  Continue to take share from compounders  Grow Makena @Home administration  Greater share of voi

  8. Slide 8: Makena subcutaneous auto-injector and exclusivity

     Makena intramuscular (IM) ‒ Only approved product to lower the risk of preterm birth ‒ Most frequent AE is injection site pain1  Makena exclusivity and patents ‒ IM orphan drug exclusivity through February 2018 ‒ Auto-injector covered by multiple issued Antares patents to 2026 ‒ Additional patent

  9. Slide 9: CBR: Attractive Recurring Revenue Stream

    9 CBR: Attractive Recurring Revenue Stream W O M E N ’ S H E A L T H : C O R D B L O O D R E G I S T R Y $24.1 $99.6 2015 2016 $118.6 2015 2016 GAAP Full Year Revenue ($M) $116.6 Non-GAAP, Pro Forma Full Year Revenue2,3 ($M) 1 Represents revenues from August 17, 2015 to December 31, 2015. CBR was ac

  10. Slide 10: Feraheme: Differentiated Product, Expect Future Growth

    10 $23.2 $26.3 4Q-2015 4Q-2016 Feraheme: Differentiated Product, Expect Future Growth $88.5 $97.1 2015 2016 Fourth Quarter Revenue1 ($M) Full Year Revenue1 ($M) 2017 Growth Drivers  Continued growth in key segments  Optimize net revenue per gram  Prepare for expanded label to include IDA patients

  11. Slide 11: GAAP Total Revenue and Operating Income

    GAAP Total Revenue and Operating Income 11 $108.7 $151.6 +39% 1 Collaboration revenue related to the termination of AMAG’s ex-US ferumoxytol marketing partnership agreement. 3-months ended December 31 ($M) $22.7 $14.6 12-months ended December 31 ($M) 4Q-2015 4Q-2016 $418.3 $532.1 $111.2 $78.9 2015 2

  12. Slide 12: GAAP Financial Summary

    GAAP Financial Summary For the 3- and 12- Months Ended December 31 ($M, except per share data) Total revenues Costs and expenses Operating income Interest expense and other Net income (loss) before taxes Income tax expense (benefit) Net income (loss) Net income (loss) per basic share Net income (los

  13. Slide 13: Non-GAAP Total Revenue and Adjusted EBITDA

    Non-GAAP Total Revenue and Adjusted EBITDA 13 $120.6 $153.0 +27% 3-months ended December 31 ($M) $61.3 $77.4 12-months ended December 31 ($M) 4Q-2015 4Q-2016 $397.4 $549.1 $213.4 $265.7 2015 2016 +38% Makena CBRFeraheme/MuGard Collaboration revenue4 Adjusted EBITDA 1 Represents CBR revenues from Aug

  14. Slide 14: Strong Cash Flow Generation

    Strong Cash Flow Generation 14 ($M) 12/31/16 12/31/15 Cash, cash equivalents and investments $5791 $466 Principal debt outstanding Convertible senior notes (2.5%) $200 $200 Term loan facility (4.75%) 328 346 2023 senior notes (7.875%) 500 500 Total debt outstanding $1,028 $1,046 ($M) 12/31/16 12/31/

  15. Slide 15: Strong Financial Profile, Management Team & Corporate Infrastructure

    Strong Financial Profile, Management Team & Corporate Infrastructure Market Access, Analytics, and Other Commercial Functions Continuing to Expand AMAG’s Product Portfolio 15 Future Product Digital Consumer Marketing Expertise, Public Relations and Medical Affairs Women’s Health (Including Maternal

  16. Slide 16: Intrarosa (prasterone)

    IntrarosaTM (prasterone) A first-of-its-kind, non-estrogen women’s health therapy

  17. Slide 17: Exclusive U.S. License for Intrarosa

    Exclusive U.S. License for Intrarosa  Will address a significant unmet need for post-menopausal women  Strong safety and efficacy profile  Large near-term commercial opportunity ‒ FDA approved in November 2016 ‒ 3 Orange Book listed patents out to 2031  Leverages AMAG’s current commercial platfo

  18. Slide 18: Intrarosa: Potential to Address Significant Unmet Need

    Intrarosa: Potential to Address Significant Unmet Need 18  Approximately 32M post-menopausal women in the U.S. suffer from symptoms of vulvar and vaginal atrophy (VVA)1 - 44% to 78% of women with VVA report symptoms of moderate-to-severe dyspareunia1,2 - Growing population of post-menopausal women

  19. Slide 19: Overview: Vulvovaginal Atrophy (VVA)

    Overview: Vulvovaginal Atrophy (VVA)1 19 3 2 W O M E N ’ S H E A L T H : I N T R A R O S A  Intrarosa is indicated for moderate-to-severe dyspareunia (pain during intercourse), a symptom of VVA, due to menopause  Post-menopausal VVA: - Common and underreported condition associated with decreased s

  20. Slide 20: Intrarosa non-estrogen mechanism, efficacy and safety

    Non-Estrogen- Based  Intrarosa contains prasterone (DHEA), a precursor of hormones that is converted locally inside the vaginal cells into androgens and estrogens  Does not carry the boxed warning that is currently required in the labels of all estrogen-containing vaginal therapies ‒ Class labelin

  21. Slide 21: Intrarosa: Sizable Untapped Market for Treating Dyspareunia

    Affected, but not yet seeking treatment Utilizing OTC treatments Previous estrogen therapy users Intrarosa: Sizable Untapped Market for Treating Dyspareunia 21 Currently on Rx estrogen therapy Safety concerns about estrogen- containing treatment options Efficacy and/or safety concerns about estrogen

  22. Slide 22: Intrarosa Serves Significant Unmet Medical Need

    Intrarosa Serves Significant Unmet Medical Need 22 1.7 M on estrogen therapy2 Local (intra-vaginal) estrogen therapies = sales of >$1B per year1 Brand(s) Current Intra-vaginal Therapies Intrarosa Administration Vaginal insert or cream by applicator Vaginal insert by applicator Indication Approved fo

  23. Slide 23: Leverages AMAG's Current Commercial Platform

    Leverages AMAG’s Current Commercial Platform  Leverage existing AMAG commercial and medical affairs teams - Deep relationships and experience with the OB/GYN community and women’s health KOLs - Successful patient access and commercial analytics platform - Strong record of consistent growth (40% in

  24. Slide 24: AMAG: At the Nexis of Key Drivers in Women's Health

    AMAG: At the Nexis of Key Drivers in Women’s Health Science Patients Healthcare Providers W O M E N ’ S H E A L T H : I N T R A R O S A Awareness-building capabilities and novel product create transformational opportunity  New mechanism of action  New therapeutic class  Only non-estrogen therapy

  25. Slide 25: Intrarosa: Designed to Build Long-Term Shareholder Value

    • $50M upfront cash payment and 600K shares of AMAG stock • Up to $10M on delivery of commercial supply for launch • $10M on the first anniversary of the effective date of the agreement • Sales milestones • $15M payment when net sales exceed $150M annually • $30M payment when net sales exceed $300M

  26. Slide 26: Upcoming Value Drivers and Potential Product Launches

    Upcoming Value Drivers and Potential Product Launches Frank Thomas President and Chief Operating Officer

  27. Slide 27: AMAG Portfolio: Multiple Value Drivers

    AMAG Portfolio: Multiple Value Drivers 27 Milestone 2017 2018 MAKENA AUTO-INJECTOR PROGRAM Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Topline PK data sNDA submission Expected FDA action and commercial launch FERAHEME IDA LABEL EXPANSION Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Enrollment completed Topline data sNDA submission Expected

  28. Slide 28: Key Product Launch Milestones

    Key Product Launch Milestones 28 Makena subcutaneous auto-injector Velo (severe preeclampsia) IDA (non-CKD) R ev e nu e Today 2017 2018 2019 2020 5 Potential Product Launches over Next 4 Years

  29. Slide 29: AMAG Pharmaceuticals Q&A

    AMAG Pharmaceuticals Q&A February 14, 2017

  30. Slide 30: Appendix

    Appendix

  31. Slide 31: Reconciliation of GAAP to Non-GAAP 2016 Results

    Reconciliation of GAAP to Non-GAAP 2016 Results 31 ($M) GAAP operating income Purchase accounting adjustments related to CBR deferred revenue Non-cash collaboration revenue Depreciation & intangible asset amortization Inventory reserve Non-cash inventory step-up adjustments Stock-based compensation

  32. Slide 32: Share Count Reconciliation

    Share Count Reconciliation 32 (M) Weighted average basic shares outstanding Employee equity incentive awards Convertible notes Warrants GAAP diluted shares outstanding Employee equity incentive awards Convertible notes Effect of bond hedge and warrants Non-GAAP diluted shares outstanding 4Q-2016 4Q-

  33. Slide 33: AMAG Pharmaceuticals 2016 Financial Results and Intrarosa License Agreement

    AMAG Pharmaceuticals 2016 Financial Results and Intrarosa License Agreement February 14, 2017

Amag Pharmaceuticals — FY2016 Earnings Presentation on 6ix